2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Breast Neoplasms
294
Lymphoma
204
Lymphoma, Large B-Cell, Diffuse
168
Sarcoma
142
Precursor Cell Lymphoblastic Leukemia-Lymphoma
110
Hodgkin Disease
85
Lymphoma, Non-Hodgkin
79
Burkitt Lymphoma
67
Lymphoma, Follicular
62
Leukemia
58
Ovarian Neoplasms
51
Triple Negative Breast Neoplasms
50
Neoplasms
50
Lymphoma, Mantle-Cell
48
Multiple Myeloma
47
Carcinoma, Hepatocellular
47
Neuroblastoma
44
Neoplasm Metastasis
42
Lymphoma, B-Cell
33
Lymphoma, Large-Cell, Anaplastic
31
Recurrence
27
Lymphoma, T-Cell, Peripheral
27
Osteosarcoma
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
25
Liposarcoma
25
Leiomyosarcoma
25
Urinary Bladder Neoplasms
23
Lymphoma, Large-Cell, Immunoblastic
23
Liver Neoplasms
22
Endometrial Neoplasms
21
Interventions
Cyclophosphamide
18
ofatumumab
14
fludarabine
12
Rituximab
11
ibrutinib
10
fludarabine phosphate
9
acalabrutinib
7
obinutuzumab
6
Lenalidomide
6
Bendamustine Hydrochloride
6
venetoclax
5
pirtobrutinib
4
Vincristine
4
Mesna
4
Melphalan
4
Immunotherapy, Adoptive
4
Whole-Body Irradiation
3
Mycophenolic Acid
3
Chlorambucil
3
Bortezomib
3
Alemtuzumab
3
spebrutinib
2
navitoclax
2
idelalisib
2
Tacrolimus
2
Tablets
2
Stem Cell Transplantation
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
KW-2478
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Leukemia, B-Cell
×
Doxorubicin
×
Clear all
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled
NCT03899337
2023-01-09
STELLAR
University of Birmingham
Phase 2
Recruiting
105 enrolled